STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Starling Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.46+0.03 (+0.47%)
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.64 (+69.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Starling Oncology, Inc. grew revenue 38.4% to $587.24M over the twelve months to Jun 30, 2026. Free cash flow was -$3.29M.
Revenue
$587.24M
+38.4% vs. a year earlier
Operating income
-$26.09M
TTM Q2 2026
Free cash flow
-$3.29M
TTM Q2 2026
EPS, diluted
-$0.30
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $665.58M
- P/E ratio
- –
- Price to sales
- 1.13
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.49%
Fundamentals
- Revenue
- $587.24M
- Net income
- -$36.29M
- EPS, diluted
- -$0.30
- Free cash flow
- -$3.29M
- Book value per share
- -$0.24
- Diluted shares
- 103M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$587.24M+38.4% YoY
Operating income
-$26.09M
Net income
-$36.29M
EPS, diluted
-$0.30
Free cash flow
-$3.29M
Reported periodTrailing twelve months